Strs Ohio decreased its position in ABIOMED, Inc. (NASDAQ:ABMD) by 38.3% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 70,867 shares of the company’s stock after selling 44,000 shares during the period. Strs Ohio’s holdings in ABIOMED were worth $7,745,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the company. State Street Corp raised its position in shares of ABIOMED by 56.3% in the first quarter. State Street Corp now owns 1,316,168 shares of the company’s stock worth $124,787,000 after buying an additional 474,209 shares during the period. Renaissance Technologies LLC raised its position in shares of ABIOMED by 152.5% in the first quarter. Renaissance Technologies LLC now owns 287,100 shares of the company’s stock worth $27,220,000 after buying an additional 173,400 shares during the period. BNP Paribas Arbitrage SA raised its position in shares of ABIOMED by 2,409.7% in the second quarter. BNP Paribas Arbitrage SA now owns 16,062 shares of the company’s stock worth $1,755,000 after buying an additional 15,422 shares during the period. Granahan Investment Management Inc. MA raised its position in shares of ABIOMED by 11.6% in the first quarter. Granahan Investment Management Inc. MA now owns 322,383 shares of the company’s stock worth $30,565,000 after buying an additional 33,400 shares during the period. Finally, TIAA CREF Investment Management LLC raised its position in shares of ABIOMED by 4.6% in the first quarter. TIAA CREF Investment Management LLC now owns 179,747 shares of the company’s stock worth $17,042,000 after buying an additional 7,886 shares during the period. 93.65% of the stock is currently owned by institutional investors and hedge funds.
Shares of ABIOMED, Inc. (NASDAQ:ABMD) traded down 0.61% during mid-day trading on Monday, hitting $127.80. The company’s stock had a trading volume of 364,925 shares. The company has a market cap of $5.47 billion, a PE ratio of 135.96 and a beta of 0.75. The stock has a 50-day moving average of $122.08 and a 200-day moving average of $108.59. ABIOMED, Inc. has a 12-month low of $67.81 and a 12-month high of $131.16.
ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.06. ABIOMED had a return on equity of 11.86% and a net margin of 11.75%. The business had revenue of $103 million for the quarter, compared to the consensus estimate of $97.23 million. During the same period in the prior year, the business earned $0.20 earnings per share. The business’s revenue was up 40.3% on a year-over-year basis. On average, equities research analysts forecast that ABIOMED, Inc. will post $1.17 EPS for the current year.
A number of research analysts have weighed in on the company. Leerink Swann restated an “outperform” rating and issued a $125.00 price objective on shares of ABIOMED in a report on Wednesday, September 28th. Zacks Investment Research lowered ABIOMED from a “buy” rating to a “hold” rating in a report on Friday, August 12th. Finally, Jefferies Group raised their price objective on ABIOMED from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. ABIOMED presently has a consensus rating of “Buy” and an average price target of $115.59.
In other news, Director Dorothy E. Puhy sold 5,160 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $123.94, for a total value of $639,530.40. Following the sale, the director now directly owns 24,749 shares in the company, valued at $3,067,391.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dorothy E. Puhy sold 3,900 shares of the company’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $122.31, for a total value of $477,009.00. Following the completion of the sale, the director now owns 33,811 shares in the company, valued at $4,135,423.41. The disclosure for this sale can be found here. 10.00% of the stock is owned by insiders.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.